Estimated Reading Time: 7 minutes

The mega-profit pharmaceutical industry relies on connections with the agency tasked with regulating it. This week, three members of an 11 member FDA advisory committee of experts resigned in protest over the FDA’s approval of Aduhelm (aducanumab) for the treatment of Alzheimer’s disease. These resignations are extremely unusual, but in this case, understandable. Aduhelm was […]